Crossject and the US Department of Defense Renew their Technology Partnership

Crossject, a pharmaceutical company specializing in needle-free auto-injectors, has announced the renewal of its research and development cooperation agreement with the U.S. Department of Defense (DOD). This partnership, initially signed in 2019, aims to evaluate an improved version of Crossject's proprietary ZENEO® auto-injector.

This device allows for the rapid and easy administration of life-saving medications, particularly useful for military personnel and first responders. Patrick Alexandre, Chief Executive Officer of Crossject, emphasizes the importance of this collaboration with the DOD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.